No abstract available.
Human papillomavirus 16 ; Vaccination

The aim of this study was to determine whether viral type HPV-6 and HPV-11 could have influence on the clinical course of recurrent respiratory papillomatosis in children. The detection of viral typing, using the polymerase chain reaction (PCR) was performed on papilloma biopsies of 36 patients at ENT Hospital HCM City from 3/2000 to 3/2004. HPV-6 was detected in 17 patient's biopsies and HPV-11 in 19 biopsies. After the findings, patients infected by HPV-11 have more aggressive than patients infected by HPV-6 (73.7% vs 29.4%; p=0.008). Patients with HPV-11 have higher prevalence of tracheotomy and shorter interval time between two operations than patients with HPV-6
Papilloma ; Respiratory system ; epidemiology ; human papillomavirus 11 ; human papillomavirus 6

Study on the incidence rate of cervical cancer on 1.122 women aged from 15 to 69 years old were interviewed and had a gynaecological examination in an urban district of HoChiMinh city. HPV DNA detection was performed using a GP5+/6+ primer-mediated PCR enzyme immunoassay. IgG antibodies against herpes simplex virus (HSV-2) were determined in blood samples using an ELISA assay. The results showed that: HPV DNA was detected among 10.9% of women in HoChiMinh city. 28 different HPV types were detected, the most common being HPV 16 (in 14 single and 18 multiple infections), followed by HPV 58, 18 and 56. A peak of HPV DNA detection in women below age 25 was found. Major risk factors for HPV DNA detection in the multivariate analyses were: indicators of sexual habits, most notably the presence of HSV-2 antibodies, nulliparity and the current use of oral contraceptives
Human papillomavirus 16 ; Human papillomavirus 18 ; epidemiology ; women

Objective: To determine the prevalence and describe the clinical characteristics of high risk HPV mong patients with oropharyngeal squamous cell carcinomas in our institution utilizing p16 and HPV DNA in-situ hybridization testing and to determine the factors associated with high risk HPV positivity. Methods: Design: Retrospective Cohort Review Setting: Tertiary Private Training Hospital Participants: 29 Results: A total of 29 primary oropharyngeal squamous cell carcinomas were diagnosed during the 11-year study period (January 2010 to December 2021). Based on the HPV in-situ hybridization status, the prevalence of high risk HPV oropharyngeal squamous cell carcinoma in our institution was 52%. Majority of these cases were males (87.5%) with a median age of ≤55 years old (60%) who are non-smokers (88.2%) and non-drinkers of alcoholic beverages (80%). There was no statistically significant association between age group, sex, smoking status, alcohol intake, lymph node status and high risk HPV infection. The most common tumor site involved in HPV-positive oropharyngeal squamous cell carcinoma was the tonsil (87%). Majority demonstrated a nonkeratinizing histology (73%) with positive lymph node status (67%) upon clinical presentation. Fifteen (83%) of the 18 p16 positive squamous cell carcinomas were positive for high risk HPVDNA. Of note, 3 (17%) out of the 18 p16 positive squamous cell carcinomas turned out to have negative HPV DNA-ISH status. Conclusion Although no statistically significant correlation between any clinical characteristic with viral status was established, HPV-mediated oropharyngeal squamous cell carcinoma in this institution was commonly seen among males aged 54 years old and below who are nonsmokers and non-drinkers of alcoholic beverages with the palatine tonsil as the most common site presenting with a non-keratinizing histology. In terms of testing, p16 staining correlates well with high risk HPV status. Future studies utilizing a larger patient population may aid in elucidating statistically significant clinical associations in our local population
human papillomavirus ; oropharyngeal cancer ; p16

Certain human papillomavirus (HPV) types are strongly associated with cervical cancer. Recently-described effective vaccines against these HPV types represent a great medical breakthrough in preventing cervical cancer. In Malaysia, the vaccine has just received regulatory approval. We are likely to face similar barriers to implementing HPV vaccination as reported by countries where vaccination has been introduced. Most women have poor understanding of HPV and its link to cervical cancer. Physicians who will be recommending HPV vaccines may not have extensive knowledge or experience with HPV-related disease. Furthermore, a vaccine against a sexually-transmitted infection may elicit negative reactions from potential recipients or their cares, particularly in a conservative society. Given the high cost of the vaccine, reaching the most vulnerable women is a concern. To foster broad acceptance of HPV vaccine, education must be provided to health care providers, parents and young women about the risks of HPV infection and the benefits of vaccination.
Papillomavirus, Human ; Vaccines ; Human Females ; Vaccination ; Malaysia

OBJECTIVETo analyze the infection condition of human papillomavirus (HPV) type 16 and 18 in the squamous cells and columnar cells of patients with common anorecatal lesions.

METHODSInfections of HPV type 16 and 18 were determined with real-time fluorescent quantitative PCR in the wax-embedded surgical specimen of 805 patients with common anorectal diseases.

RESULTSThe overall infection rate among 805 patients with anorecatal lesions was 66.1% (532/805). The infection rate was 82.6% (95/115) in patients with mixed hemorrhoids, 76.5% (88/115) in anal papillary fibromas, 74.8% (86/115) in internal hemorrhoids, 72.2% (83/115) in fistulas, 69.6% (80/115) in external hemorrhoids, 47.8% (55/115) in anal perianal abscesses, and 39.1% (45/115) in anal fissures.

CONCLUSIONInfection rate of HPV type 16, 18 in common anorectal lesions is high.

Human papillomavirus 16 ; Human papillomavirus 18 ; Humans ; Papillomavirus Infections ; Rectal Diseases ; epidemiology

The efficacy of HPV vaccine in preventing cervical cancer has been demonstrated in numerous clinical trials and clinical uses. The follow-up after clinical trials usually last for 5-6 years to evaluate the long-term efficacy, and a series of long-term follow-up studies have been conducted in some regions. The literature retrieval of HPV vaccine long term efficiency research both at home and abroad indicated that the protective efficacy of the vaccine against vaccine-type-related cervical intraepithelial neoplasia grade 2 and above is higher than 90%.
Humans ; Human Papillomavirus Viruses ; Biomedical Research ; Papillomavirus Vaccines

Objective: To determine the prevalence of HPV high risk positivity among women patients ages 30 to 65 with biopsyproven external genital warts (condyloma acuminata) specifically for HPV 16, HPV 18, and for other high risk types 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66/68, 73, and 82. Methodology: A cross-sectional study was conducted at the Department of Obstetrics and Gynecology Out-Patient Services of the Philippine General Hospital involving 57 women, 30 to 65 years old, with biopsy proven external genital warts or condyloma acuminata. These women underwent human papillomavirus (HPV) genotyping test for the high risk types (HR-HPV) from cervical samples using the automated polymerase chain reaction (PCR) technology. Results: Fifteen out the 57 subjects had at least one of the HR-HPV types for an overall prevalence of 26.3%. Of the 15, 8 (53.3%) had at least 2 HR-HPV types with one subject having the most number of types at 6. Among the strains, the most common is HPV 51 and 52 each with a prevalence of 8.77% followed by HPV 53 and 59 at 7% each. HPV 16 and 18 each only had a 3.5% prevalence the same as HPV 58, 73, and 82. HR-HPV positivity was most common in the 30 to 39 age group (80%), and equally in the nulligravid and the secundigravid (40% each). None had current or past cigarettesmoking history and 33% had some form of hormonal contraception. Conclusion The overall prevalence of high risk HPV (HR-HPV) among these 57 Filipino women with external genital warts is 26.3%. The higher prevalence of HPV 51, 52, 53, and 59 over HPV 16 and 18 in this group does not follow the usual epidemiological characteristics reported about this disease.
Outpatients ; Human papillomavirus 16 ; Philippines ; Papillomaviridae

BACKGROUND: Human Papilloma Virus (HPV) has been known to be an important factor in the development of cervical cancer. In 2006, two vaccines were made available in the Philippines, one covering two subtypes (HPV 16 and 18) and the other covers four subtypes (HPV 6, 11, 16 and 18) of the virus.

OBJECTIVES: This study aimed to determine the current knowledge, attitude, and practices of obstetrics and gynecology residents from both government and private sector regarding HPV vaccination as well as determine barriers to vaccination. It also aimed to determine if there is any disparity between the private and government setting, and between residency year levels which may create a discrepancy in the vaccination coverage of their patients.

METHODS: Data will be collected through a self-administered questionnaire. The survey to be used in this study was adapted from the form used in a similar study done in Hong-Kong. The questionnaire will consist of five sections: 1) items regarding the respondents' demographics (age; sex; institution type; residency training year level; number of patients seen in a typical week; number of patients seen in a week aged 10-17, 18-26, and 27-45; number of pap smears performed in a typical week), 2) Knowledge on human papillomavirus infection, 3) Attitude towards HPV vaccine, 4) HPV vaccination practice, and 5) Perceived barriers in HPV vaccination.

RESULTS: This study found that the knowledge of residents about human papilloma virus was generally poor to fair with no significant difference between the knowledge of residents from government institutions compared to those from the private sector. Majority of the residents believe that the vaccine should be administered to 10-17 years old, prior to sexual debut and exposure to the human papilloma virus but were not able to prescribe vaccination for this age group. The perceived barriers of residents in prescribing and vaccinating their patients differ between age groups. For 10-17 years old, parental refusal for vaccinating their children is due to the notion that in doing so, their child is being singled out as being at risk for sexually transmitted diseases. For patients 18-26 years old, residents believe that their reluctance to discuss and talk about issues of sexuality are likely to hinder them from getting vaccinated. For the 27-45-year-old age group, the residents believe that the patient's belief that they do not have HPV infection is likely to hinder them being vaccinated.

CONCLUSION: Proper education and good communication skills among residents and patients should be developed to properly employ and promote vaccination.

Human ; Male ; Female ; Adult ; Adolescent ; Child ; Human Papillomavirus 16 ; Papillomavirus Infections ; Papanicolaou Test ; Human Papillomavirus 6 ; Papillomavirus Vaccines ; Vaccination ; Sexually Transmitted Diseases

BACKGROUND: Human Papilloma Virus (HPV) has been known to be an important factor in the development of cervical cancer. In 2006, two vaccines were made available in the Philippines, one covering two subtypes (HPV 16 and 18) and the other covers four subtypes (HPV 6, 11, 16 and 18) of the virus.

OBJECTIVES: This study aimed to determine the current knowledge, attitude, and practices of obstetrics and gynecology residents from both government and private sector regarding HPV vaccination as well as determine barriers to vaccination. It also aimed to determine if there is any disparity between the private and government setting, and between residency year levels which may create a discrepancy in the vaccination coverage of their patients.

METHODS: Data will be collected through a self-administered questionnaire. The survey to be used in this study was adapted from the form used in a similar study done in Hong-Kong. The questionnaire will consist of five sections: 1) items regarding the respondents' demographics (age; sex; institution type; residency training year level; number of patients seen in a typical week; number of patients seen in a week aged 10-17, 18-26, and 27-45; number of pap smears performed in a typical week), 2) Knowledge on human papillomavirus infection, 3) Attitude towards HPV vaccine, 4) HPV vaccination practice, and 5) Perceived barriers in HPV vaccination.

RESULTS: This study found that the knowledge of residents about human papilloma virus was generally poor to fair with no significant difference between the knowledge of residents from government institutions compared to those from the private sector. Majority of the residents believe that the vaccine should be administered to 10-17 years old, prior to sexual debut and exposure to the human papilloma virus but were not able to prescribe vaccination for this age group. The perceived barriers of residents in prescribing and vaccinating their patients differ between age groups. For 10-17 years old, parental refusal for vaccinating their children is due to the notion that in doing so, their child is being singled out as being at risk for sexually transmitted diseases. For patients 18-26 years old, residents believe that their reluctance to discuss and talk about issues of sexuality are likely to hinder them from getting vaccinated. For the 27-45-year-old age group, the residents believe that the patient's belief that they do not have HPV infection is likely to hinder them being vaccinated.

CONCLUSION: Proper education and good communication skills among residents and patients should be developed to properly employ and promote vaccination.

Human ; Male ; Female ; Adult ; Adolescent ; Child ; Human Papillomavirus 16 ; Papillomavirus Infections ; Papanicolaou Test ; Human Papillomavirus 6 ; Papillomavirus Vaccines ; Vaccination ; Sexually Transmitted Diseases